The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Any genotype

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer

Phase 1 · randomised · 542 people · 84 sites in 11 countries · Recruiting now

August 7, 2026
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Phase 3 · randomised · 1,083 people · 1 site in Spain · Recruiting now

August 7, 2026
Safety of HRX215 in Patients After Minor and Major Liver Resection

Phase 2 · randomised · 80 people · 12 sites in 5 countries · Recruiting now

August 7, 2026
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 2 · 560 people · 54 sites in 7 countries · Recruiting now

August 7, 2026
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Phase 2 · randomised · 80 people · 76 sites in 12 countries · Recruiting now

August 7, 2026
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

Phase 3 · randomised · 131 people · 4 sites in 2 countries · Recruiting now

August 7, 2026
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Phase 2 · randomised · 170 people · 14 sites in 4 countries · Recruiting now

August 7, 2026
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Phase 2 · randomised · 86 people · 6 sites in United States · Recruiting now

August 7, 2026
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer

Phase 3 · randomised · 236 people · 3 sites in South Korea · Recruiting now

August 7, 2026
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Phase 3 · randomised · 250 people · 113 sites in 2 countries · Recruiting now

August 7, 2026